Uncategorized
November 1, 2023 / January 12, 2026 by necteromedical
TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System to treat patients with infrarenal AAAs, maximum diameter 3.5 – 5.0cm. Nectero Therapeutics is initiating […]
Read more »
August 24, 2023 / January 12, 2026 by necteromedical
TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System to treat patients with infrarenal AAAs, maximum diameter 3.5 – 5.0cm. Nectero Therapeutics is initiating […]
July 24, 2023 / January 12, 2026 by necteromedical
Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease and improve patients’ lives, today announced that the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance for the company to initiate a prospective, multi-center, randomized clinical trial (the stAAAble Study) to evaluate the safety and efficacy of the […]
September 10, 2021 / January 12, 2026 by necteromedical
Proceeds from new investors will fund in vivo and clinical development of innovative platform for aneurysmal disease, including Abdominal Aortic Aneurysms (AAA) TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Therapeutics Inc. today announced the closing of its $19.5 million Series C financing round, led by new investor Boston Scientific Corporation, a leading global medical device manufacturer. Proceeds will support the company’s in […]